PMCB - PharmaCyte Biotech more than doubles in value after NASDAQ uplisting

Nano cap stock PharmaCyte Biotech (PMCB +118.4%) has added over twofold in value intraday on above-average volume of shares. So far, ~142.9M PharmaCyte shares have changed hands, more than 33 times the average share volume over the past 65-day period. Last week, the company announced that its shares will be moving to The Nasdaq Capital Market on August 10 for trading from the over-the-counter market. The gains have approached 150% since then. PharmaCyte (NASDAQ:PMCB), a development-stage biotech company focused on cellular therapies for cancer and diabetes, also announced the pricing of its underwritten public offering that aimed for $15M in gross proceeds. Previously in July, PharmaCyte (PMCB) announced a 1-for-1,500 reverse stock split of its common stock, a necessary step for listing the shares in national stock exchange like Nasdaq.

For further details see:

PharmaCyte Biotech more than doubles in value after NASDAQ uplisting